Additionally, while only 8.1% ( N = 24 203) of ODB beneficiaries were dispensed a respiratory inhaler from the ICS/LAMA/LABA drug class in Q1 of 2023, uptake has remained on an increasing trend since initial listing on the ODB formulary in Q3 of 2019.
← all excerpts
Trends in the Cost and Utilization of Publicly Dispensed Respiratory Inhalers in Ontario, Canada: A Repeated Cross-Sectional Study.
1
—
—